

ACELRX PHARMACEUTICALS INC  
Form 8-K  
October 12, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 12, 2017**

**ACELRX PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**                      **001-35068**                      **41-2193603**  
(State of incorporation) (Commission File No.) (IRS Employer Identification No.)

**351 Galveston Drive**

**Redwood City, CA 94063**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 216-3500**

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On October 12, 2017, AcelRx Pharmaceuticals, Inc. (the “Company” or “AcelRx”) issued a press release that disclosed that the Company’s estimated cash balance as of September 30, 2017 was \$67.9 million. The aforementioned financial information is included in the press release, as furnished in Exhibit 99.1 to this Current Report and is incorporated herein by reference.

**Item 8.01 Other Events.**

On October 12, 2017, the Company issued a press release entitled “AcelRx Pharmaceuticals Receives Complete Response Letter from the FDA for DSUVIA™ NDA,” a copy of which is attached as Exhibit 99.1 to this Report.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit

Number	Description
99.1	Press release dated October 12, 2017

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 12, 2017 ACELRX PHARMACEUTICALS,  
INC.

By: /s/ Jane  
Wright-Mitchell  
Jane  
Wright-Mitchell  
  
Chief Legal  
Officer

---

EXHIBIT INDEX

Exhibit

Number	Description
99.1	<u>Press release dated October 12, 2017</u>